Published in Cytotherapy on August 17, 2012
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood (2014) 2.00
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia (2013) 1.52
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica (2015) 1.02
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One (2013) 1.02
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother (2015) 1.01
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res (2013) 1.00
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol (2013) 0.97
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front Immunol (2014) 0.95
Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells. Front Immunol (2016) 0.95
Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev (2014) 0.93
GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One (2013) 0.92
Antiviral T-cell therapy. Immunol Rev (2014) 0.91
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother (2014) 0.88
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88
Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant (2014) 0.86
Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res (2014) 0.85
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology (2015) 0.84
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med (2016) 0.82
Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant (2015) 0.81
The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia (2015) 0.81
Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm (2014) 0.80
Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev (2014) 0.80
Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog (2014) 0.80
Adoptive cell therapy for sarcoma. Immunotherapy (2015) 0.78
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis. PLoS One (2014) 0.78
Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy. Front Immunol (2013) 0.77
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front Immunol (2017) 0.76
Manufacturing Natural Killer Cells as Medicinal Products. Front Immunol (2016) 0.75
Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. Breast Cancer Res Treat (2016) 0.75
Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients. Front Immunol (2017) 0.75
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul (1987) 3.45
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet (2000) 3.13
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer (2002) 1.87
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy (2010) 1.85
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol (1992) 1.75
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy (2012) 1.67
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy (2008) 1.63
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol (2001) 1.57
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion (2007) 1.49
Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 1.39
Role of monocytes in the expansion of human activated natural killer cells. Blood (1992) 1.33
Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp (2011) 1.32
Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy (2004) 1.31
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 1.28
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood (2008) 1.28
Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett (2000) 1.26
Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr (2005) 1.26
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy (2010) 1.07
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica (2012) 1.05
Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun (1998) 1.04
Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol (2010) 1.01
Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg (2003) 0.98
Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother (2009) 0.96
Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate. Hum Immunol (1985) 0.94
Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation. Mol Cell Biol (1986) 0.94
Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp Hematol (2011) 0.93
Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther (2011) 0.86
Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int (2011) 0.86
Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol (2010) 0.86
HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon. Exp Hematol (1985) 0.83
Synergistic enhancement of class I major histocompatibility complex antigen expression in K562 cells induced by recombinant human interferon-gamma and tumor necrosis factor in combination. Exp Hematol (1989) 0.78
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Improving T cell therapy for cancer. Annu Rev Immunol (2007) 3.10
Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol (2009) 2.97
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant (2007) 2.60
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol (2011) 2.31
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 1.89
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol (2010) 1.84
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood (2002) 1.74
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med (2004) 1.72
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther (2012) 1.72
Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med (2004) 1.72
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood (2011) 1.72
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol (2007) 1.70
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68